Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | FADS1 | O60427 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1091453 | 0.98 | MAPT (0.52) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL8795345 | 0.85 | MAPT (0.61) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3202726 | 0.81 | — | — | |
| SCHEMBL2481143 | 0.79 | MAPT (0.55) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL7234754 | 0.77 | MAPT (0.53) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL8714373 | 0.77 | MAPT (0.53) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL20954869 | 0.77 | MAPT (0.53) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL10669562 | 0.77 | MAPT (0.58) | MAPTALDH1A1GAAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11064752 | 0.76 | MAPT (0.56) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL1686631 | 0.75 | FADS1 (0.59) | MAPTALDH1A1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102282147-B | Bicyclic pyrazolo-heterocycles | CARA THERAPEUTICS, INC. (US) | 2015-09-30 | — | — | CN | disclosed |
| US-8653127-B2 | Bicyclic pyrazolo-heterocycles | CARA THERAPEUTICS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2391627-B1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2373641-B1 | PYRIDAZINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-8178538-B2 | Pyridazinones | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| CN-102282147-A | Bicyclic pyrazolo-heterocycles | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2391627-A2 | BICYCLIC PYRAZOLO-HETEROCYCLES | Cara Therapeutics, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110275609-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| CN-102239162-A | Pyridazinone derivatives | HOFFMANN LA ROCHE | 2011-11-09 | — | — | CN | disclosed |
| EP-2373641-A1 | PYRIDAZINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010088050-A2 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100152193-A1 | PYRIDAZINONES | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | disclosed |
| WO-2010063610-A1 | PYRIDAZINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152193-A1 | PYRIDAZINONES | PDE5A, PDE3A, PDE10A | MAPT 2313/4885ALDH1A1 251/4885GAA 752/4885 |
| US-20110275609-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CNR1, CNR2, HRH4 | MAPT 1876/4885ALDH1A1 1849/4885GAA 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.